{"hands_on_practices": [{"introduction": "The initial challenge in managing orofacial pain is achieving an accurate diagnosis, as the symptoms of trigeminal neuralgia (TN) can mimic other conditions, such as odontogenic pain. This exercise applies the principles of Bayesian inference to quantify the uncertainty in diagnosis. By starting with the pre-test probability, or prevalence, of TN in a specific clinical population, you will use the sensitivity and specificity of a diagnostic provocation test to calculate the posterior probability that a patient has the disease, a foundational skill in evidence-based medicine [@problem_id:4738411].", "problem": "In an advanced Orofacial Pain (OFP) referral clinic, a standardized mechanical provocation protocol is used to differentiate trigeminal neuralgia (TN) from suspected dental-origin pain. The protocol consists of innocuous tactile stimulation over a suspected trigger zone; a positive response is defined as immediate, sharp, unilateral paroxysmal pain with latency less than $0.5$ seconds resolving spontaneously within $2$ minutes. Assay validation against blinded adjudication by expert panel consensus shows the following operating characteristics with respect to TN versus non-TN dental-origin pain: sensitivity $0.90$ and specificity $0.95$. In the clinic’s referral stream, the pretest prevalence of TN is $0.05$.\n\nAssume the test result is positive for a newly referred patient. Starting from the axiomatic definitions of conditional probability and the law of total probability, derive the posterior probability that the patient actually has TN given a positive test. This posterior probability is used to decide whether to proceed with first-line carbamazepine titration subject to Pharmacogenomics (PGx) screening for Human Leukocyte Antigen B*15:02 (HLA-B*15:02) and cytochrome P450 family 2 subfamily C member 9 ($CYP2C9$) variants.\n\nYou must:\n- Treat the sensitivity as $P(T^{+} \\mid \\mathrm{TN})$ and specificity as $P(T^{-} \\mid \\neg \\mathrm{TN})$, where $T^{+}$ denotes a positive provocation test.\n- Use only foundational probability definitions and do not invoke preassembled clinical “shortcut” formulas.\n- Express the final posterior probability $P(\\mathrm{TN} \\mid T^{+})$ as a single exact fraction in simplest terms. Do not use a percentage sign. No rounding is required.", "solution": "The problem is evaluated to be scientifically grounded, well-posed, objective, and internally consistent, thus meeting all criteria for a valid problem statement. We may therefore proceed with a formal solution.\n\nThe objective is to derive the posterior probability that a patient has trigeminal neuralgia ($\\mathrm{TN}$) given a positive test result ($T^{+}$), denoted as $P(\\mathrm{TN} \\mid T^{+})$. The derivation must start from foundational axiomatic definitions.\n\nLet $\\mathrm{TN}$ be the event that the patient has trigeminal neuralgia, and let $\\neg \\mathrm{TN}$ be the complementary event that the patient does not have trigeminal neuralgia. Let $T^{+}$ be the event of a positive test result.\n\nThe givens from the problem statement are:\n1.  The pretest prevalence of trigeminal neuralgia: $P(\\mathrm{TN}) = 0.05$.\n2.  The sensitivity of the test: $P(T^{+} \\mid \\mathrm{TN}) = 0.90$.\n3.  The specificity of the test: $P(T^{-} \\mid \\neg \\mathrm{TN}) = 0.95$, where $T^{-}$ is the event of a negative test result.\n\nWe begin with the axiomatic definition of conditional probability, which states that for any two events $A$ and $B$, where $P(B) > 0$:\n$$P(A \\mid B) = \\frac{P(A \\cap B)}{P(B)}$$\n\nApplying this definition to our target probability, $P(\\mathrm{TN} \\mid T^{+})$, we have:\n$$P(\\mathrm{TN} \\mid T^{+}) = \\frac{P(\\mathrm{TN} \\cap T^{+})}{P(T^{+})}$$\n\nThe numerator, $P(\\mathrm{TN} \\cap T^{+})$, can be expressed by rearranging the conditional probability definition for sensitivity, $P(T^{+} \\mid \\mathrm{TN})$:\n$$P(T^{+} \\mid \\mathrm{TN}) = \\frac{P(T^{+} \\cap \\mathrm{TN})}{P(\\mathrm{TN})}$$\n$$P(\\mathrm{TN} \\cap T^{+}) = P(T^{+} \\mid \\mathrm{TN}) P(\\mathrm{TN})$$\n\nThe denominator, $P(T^{+})$, is the total probability of a positive test. We can expand this term using the law of total probability. The sample space is partitioned by the events $\\mathrm{TN}$ and $\\neg \\mathrm{TN}$. Therefore, the event $T^{+}$ can be written as the union of two disjoint events: $(T^{+} \\cap \\mathrm{TN})$ and $(T^{+} \\cap \\neg \\mathrm{TN})$.\n$$P(T^{+}) = P(T^{+} \\cap \\mathrm{TN}) + P(T^{+} \\cap \\neg \\mathrm{TN})$$\n\nUsing the definition of conditional probability for each term in the sum, we get:\n$$P(T^{+}) = P(T^{+} \\mid \\mathrm{TN}) P(\\mathrm{TN}) + P(T^{+} \\mid \\neg \\mathrm{TN}) P(\\neg \\mathrm{TN})$$\n\nSubstituting the expressions for the numerator and the denominator back into our original equation for $P(\\mathrm{TN} \\mid T^{+})$ yields Bayes' theorem, derived from first principles as required:\n$$P(\\mathrm{TN} \\mid T^{+}) = \\frac{P(T^{+} \\mid \\mathrm{TN}) P(\\mathrm{TN})}{P(T^{+} \\mid \\mathrm{TN}) P(\\mathrm{TN}) + P(T^{+} \\mid \\neg \\mathrm{TN}) P(\\neg \\mathrm{TN})}$$\n\nBefore substituting the given values, we must calculate the probabilities for the complementary events:\nThe probability of not having TN is:\n$$P(\\neg \\mathrm{TN}) = 1 - P(\\mathrm{TN}) = 1 - 0.05 = 0.95$$\nThe probability of a positive test given no TN (the false positive rate) is $1$ minus the specificity:\n$$P(T^{+} \\mid \\neg \\mathrm{TN}) = 1 - P(T^{-} \\mid \\neg \\mathrm{TN}) = 1 - 0.95 = 0.05$$\n\nNow, we convert the decimal probabilities into exact fractions for the calculation:\n$P(\\mathrm{TN}) = 0.05 = \\frac{5}{100} = \\frac{1}{20}$\n$P(T^{+} \\mid \\mathrm{TN}) = 0.90 = \\frac{90}{100} = \\frac{9}{10}$\n$P(\\neg \\mathrm{TN}) = 0.95 = \\frac{95}{100} = \\frac{19}{20}$\n$P(T^{+} \\mid \\neg \\mathrm{TN}) = 0.05 = \\frac{5}{100} = \\frac{1}{20}$\n\nSubstitute these fractional values into the derived formula:\n$$P(\\mathrm{TN} \\mid T^{+}) = \\frac{\\left(\\frac{9}{10}\\right) \\left(\\frac{1}{20}\\right)}{\\left(\\frac{9}{10}\\right) \\left(\\frac{1}{20}\\right) + \\left(\\frac{1}{20}\\right) \\left(\\frac{19}{20}\\right)}$$\n\nFirst, we calculate the products in the numerator and denominator:\nNumerator:\n$$\\left(\\frac{9}{10}\\right) \\left(\\frac{1}{20}\\right) = \\frac{9}{200}$$\nDenominator terms:\n$$\\left(\\frac{9}{10}\\right) \\left(\\frac{1}{20}\\right) = \\frac{9}{200}$$\n$$\\left(\\frac{1}{20}\\right) \\left(\\frac{19}{20}\\right) = \\frac{19}{400}$$\n\nNow, we sum the terms in the denominator:\n$$P(T^{+}) = \\frac{9}{200} + \\frac{19}{400} = \\frac{18}{400} + \\frac{19}{400} = \\frac{37}{400}$$\n\nFinally, we compute the posterior probability:\n$$P(\\mathrm{TN} \\mid T^{+}) = \\frac{\\frac{9}{200}}{\\frac{37}{400}} = \\frac{9}{200} \\cdot \\frac{400}{37} = \\frac{9 \\cdot 2}{37} = \\frac{18}{37}$$\n\nThe posterior probability that the patient has trigeminal neuralgia given a positive provocation test is $\\frac{18}{37}$.", "answer": "$$\\boxed{\\frac{18}{37}}$$", "id": "4738411"}, {"introduction": "Once a diagnosis of TN is established, pharmacotherapy is initiated, but treatment selection is now guided by pharmacogenomics to prevent life-threatening adverse drug reactions. This practice explores the population-level justification for pre-prescription screening for the HLA-B*15:02 allele before using carbamazepine, a drug strongly associated with Stevens-Johnson Syndrome in carriers. You will synthesize data on allele frequencies, test performance, and differential risk to compute the expected public health impact of the screening program, demonstrating how pharmacogenomics informs clinical guidelines [@problem_id:4738399].", "problem": "A tertiary orofacial pain service in stomatology plans to implement pre-prescription Human Leukocyte Antigen (HLA) genotyping for the allele HLA-B*15:02 before initiating carbamazepine therapy for classical trigeminal neuralgia. Severe Cutaneous Adverse Reactions (SCAR), including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are the primary outcomes of concern. Your task is twofold: first, briefly explain from a population genetics standpoint why HLA-B*15:02 allele frequencies differ among East Asian, South Asian, and European groups; second, quantify the expected number of SCAR cases prevented per $10{,}000$ HLA-B*15:02 tests in this clinic’s patient mix, based on the quantitative parameters below.\n\nUse the following scientifically grounded and clinically plausible parameters. All patients tested are candidates for carbamazepine; patients with a positive test are steered to a non–HLA-B*15:02–implicated alternative with much lower SCAR risk.\n\n- Clinic’s patient ancestry mix (proportions among those tested): East Asian $= 0.50$, South Asian $= 0.30$, European $= 0.20$.\n- HLA-B*15:02 prevalence by group: East Asian $= 0.08$, South Asian $= 0.04$, European $= 0.001$.\n- HLA-B*15:02 test performance: sensitivity $= 0.995$, specificity $= 0.999$.\n- SCAR risk with carbamazepine if HLA-B*15:02 carrier: $0.05$.\n- SCAR risk with carbamazepine if HLA-B*15:02 non-carrier: $0.0005$.\n- SCAR risk with the alternative therapy (used if the test is positive): $0.00005$.\n\nAssume that a negative HLA-B*15:02 test leads to carbamazepine initiation, whereas a positive test leads to alternative therapy. Assume that SCAR risks are independent across individuals and constant within the strata given. Use fundamental probability definitions of prevalence, sensitivity, specificity, conditional risk, and expected value; do not invoke any other external formulas.\n\nCompute the expected number of SCAR cases prevented per $10{,}000$ tests when implementing this pharmacogenomic strategy compared to no genetic testing (i.e., everyone receives carbamazepine). Express the final answer as a decimal number with no units. Round your answer to three significant figures.", "solution": "We begin with core definitions from probability and epidemiology. For a given group with HLA-B*15:02 prevalence $p$, test sensitivity $\\mathrm{Se}$, specificity $\\mathrm{Sp}$, and treatment allocation rule (negative test leads to carbamazepine; positive test leads to alternative), we compute:\n\n1. The expected per-person SCAR risk without testing (everyone receives carbamazepine).\n2. The expected per-person SCAR risk with testing (allocation determined by test result).\n3. The difference (without testing minus with testing) as the per-person risk reduction.\n4. The weighted average risk reduction across the clinic’s ancestry mix.\n5. The expected number of cases prevented per $10{,}000$ tests by multiplying the average per-person reduction by $10{,}000$.\n\nFirst, we set symbols:\n- Let $p$ be HLA-B*15:02 prevalence for a group.\n- Let $\\mathrm{Se} = 0.995$, $\\mathrm{Sp} = 0.999$.\n- Let $r_{c}^{+} = 0.05$ be SCAR risk on carbamazepine if HLA-B*15:02 carrier.\n- Let $r_{c}^{-} = 0.0005$ be SCAR risk on carbamazepine if non-carrier.\n- Let $r_{a} = 0.00005$ be SCAR risk on the alternative (used if the test is positive).\n\nWithout testing, every patient receives carbamazepine. The per-person expected risk is\n$$\nR_{0}(p) = p \\, r_{c}^{+} + (1-p)\\, r_{c}^{-}.\n$$\n\nWith testing, we partition by true disease status and test result:\n- True positive with probability $p \\, \\mathrm{Se}$ receives alternative, SCAR risk $r_{a}$.\n- False negative with probability $p \\, (1-\\mathrm{Se})$ receives carbamazepine, SCAR risk $r_{c}^{+}$.\n- True negative with probability $(1-p)\\, \\mathrm{Sp}$ receives carbamazepine, SCAR risk $r_{c}^{-}$.\n- False positive with probability $(1-p)\\, (1-\\mathrm{Sp})$ receives alternative, SCAR risk $r_{a}$.\n\nThus the per-person expected risk with testing is\n$$\nR_{1}(p) = p \\, \\mathrm{Se} \\, r_{a} + p \\, (1-\\mathrm{Se}) \\, r_{c}^{+} + (1-p)\\, \\mathrm{Sp} \\, r_{c}^{-} + (1-p)\\, (1-\\mathrm{Sp}) \\, r_{a}.\n$$\n\nThe per-person risk reduction is\n$$\nD(p) = R_{0}(p) - R_{1}(p).\n$$\n\nSubstitute the given numerical values. First compute helpful intermediate quantities:\n$$\nr_{c}^{+} - r_{c}^{-} = 0.05 - 0.0005 = 0.0495,\n$$\n$$\n\\mathrm{Se}\\, r_{a} = 0.995 \\times 0.00005 = 0.00004975,\n$$\n$$\n(1-\\mathrm{Se})\\, r_{c}^{+} = 0.005 \\times 0.05 = 0.00025,\n$$\nso\n$$\nA := \\mathrm{Se}\\, r_{a} + (1-\\mathrm{Se})\\, r_{c}^{+} = 0.00004975 + 0.00025 = 0.00029975.\n$$\nNext,\n$$\n\\mathrm{Sp}\\, r_{c}^{-} = 0.999 \\times 0.0005 = 0.0004995,\n$$\n$$\n(1-\\mathrm{Sp})\\, r_{a} = 0.001 \\times 0.00005 = 0.00000005,\n$$\nso\n$$\nB := \\mathrm{Sp}\\, r_{c}^{-} + (1-\\mathrm{Sp})\\, r_{a} = 0.0004995 + 0.00000005 = 0.00049955.\n$$\n\nWe can express $R_{0}(p)$ and $R_{1}(p)$ compactly as\n$$\nR_{0}(p) = r_{c}^{-} + p \\, (r_{c}^{+} - r_{c}^{-}) = 0.0005 + 0.0495\\, p,\n$$\n$$\nR_{1}(p) = p \\, A + (1-p)\\, B = p \\times 0.00029975 + (1-p) \\times 0.00049955.\n$$\nTherefore,\n$$\nD(p) = \\bigl(0.0005 + 0.0495\\, p\\bigr) - \\bigl(0.00049955 + p \\,(0.00029975 - 0.00049955)\\bigr).\n$$\nNote that\n$$\n0.0005 - 0.00049955 = 4.5 \\times 10^{-7},\n$$\nand\n$$\n0.0495 - (0.00029975 - 0.00049955) = 0.0495 + 0.0001998 = 0.0496998.\n$$\nHence,\n$$\nD(p) = 4.5 \\times 10^{-7} + 0.0496998 \\, p.\n$$\n\nCompute $D(p)$ for each ancestry group using the provided prevalences:\n- East Asian: $p_{\\mathrm{EA}} = 0.08$, so\n$$\nD_{\\mathrm{EA}} = 4.5 \\times 10^{-7} + 0.0496998 \\times 0.08 = 0.00000045 + 0.003975984 = 0.003976434.\n$$\n- South Asian: $p_{\\mathrm{SA}} = 0.04$, so\n$$\nD_{\\mathrm{SA}} = 4.5 \\times 10^{-7} + 0.0496998 \\times 0.04 = 0.00000045 + 0.001987992 = 0.001988442.\n$$\n- European: $p_{\\mathrm{EU}} = 0.001$, so\n$$\nD_{\\mathrm{EU}} = 4.5 \\times 10^{-7} + 0.0496998 \\times 0.001 = 0.00000045 + 0.0000496998 = 0.0000501498.\n$$\n\nWeight these per-person risk reductions by the clinic’s ancestry mix to obtain the average per-person reduction $\\bar{D}$:\nLet $w_{\\mathrm{EA}} = 0.50$, $w_{\\mathrm{SA}} = 0.30$, $w_{\\mathrm{EU}} = 0.20$.\nThen\n$$\n\\bar{D} = w_{\\mathrm{EA}} D_{\\mathrm{EA}} + w_{\\mathrm{SA}} D_{\\mathrm{SA}} + w_{\\mathrm{EU}} D_{\\mathrm{EU}}.\n$$\nCompute each term:\n$$\nw_{\\mathrm{EA}} D_{\\mathrm{EA}} = 0.50 \\times 0.003976434 = 0.001988217,\n$$\n$$\nw_{\\mathrm{SA}} D_{\\mathrm{SA}} = 0.30 \\times 0.001988442 = 0.0005965326,\n$$\n$$\nw_{\\mathrm{EU}} D_{\\mathrm{EU}} = 0.20 \\times 0.0000501498 = 0.00001002996.\n$$\nSum:\n$$\n\\bar{D} = 0.001988217 + 0.0005965326 + 0.00001002996 = 0.00259477956.\n$$\n\nTherefore, the expected number of SCAR cases prevented per $10{,}000$ tests is\n$$\nN_{\\mathrm{prevented}} = 10{,}000 \\times \\bar{D} = 10{,}000 \\times 0.00259477956 = 25.9477956.\n$$\nRounding to three significant figures as requested gives\n$$\n25.9.\n$$\n\nFinally, a brief conceptual explanation of population differences: HLA-B*15:02 allele frequencies differ across East Asian, South Asian, and European groups due to population genetics principles, including historical demographic events (such as founder effects and genetic drift), natural selection pressures, and population structure with non-random mating. Over time, these forces, acting on ancestral populations that experienced partial isolation and distinct evolutionary trajectories, yielded higher frequencies in many East and some South Asian populations and very low frequencies in most European populations. These differences are well-documented in population genetic surveys and underlie the differential clinical utility of pre-prescription HLA-B*15:02 pharmacogenomic screening across ancestries.", "answer": "$$\\boxed{25.9}$$", "id": "4738399"}, {"introduction": "Pharmacogenomic findings often necessitate the use of alternative therapies, which in turn require their own careful dose adjustments based on individual patient characteristics. This problem simulates a common clinical consequence: after identifying a patient as a carrier of the HLA-B*15:02 allele and thus avoiding carbamazepine, the alternative drug pregabalin is selected. You will practice a critical skill in clinical pharmacology by adjusting the pregabalin dose based on the patient's renal function, using the Cockcroft-Gault equation to estimate creatinine clearance and ensure both safety and efficacy [@problem_id:4738357].", "problem": "A patient with classical trigeminal neuralgia and refractory neuropathic orofacial pain is being managed in a stomatology clinic. Pharmacogenomic testing reveals carriage of human leukocyte antigen B*15:02 (HLA-B*15:02) and human leukocyte antigen A*31:01 (HLA-A*31:01), and cytochrome P450 2C9 ($CYP2C9$) genotype consistent with poor metabolism. In light of the elevated risk of severe cutaneous adverse reactions and altered metabolism with sodium channel blockers and aromatic anticonvulsants, pregabalin is selected as the first-line systemic agent.\n\nThe patient is a $68$-year-old female, height $165$ cm, total body weight $85$ kg, with stable chronic kidney disease and most recent Estimated Glomerular Filtration Rate (eGFR) of $35$ mL/min per $1.73$ m$^2$ and serum creatinine (SCr) of $1.8$ mg/dL. For titration purposes, assume that pregabalin exhibits linear pharmacokinetics and is cleared almost entirely unchanged by the kidney, so that maintenance dose at steady state is directly proportional to creatinine clearance; take the reference normal creatinine clearance as $100$ mL/min. The usual effective maintenance dose in patients with normal renal function is $600$ mg/day (divided doses).\n\nUsing the Cockcroft–Gault equation to estimate creatinine clearance for this patient, with the convention that adjusted body weight is used if total body weight exceeds $120\\%$ of ideal body weight, compute the adjusted pregabalin maintenance dose for this patient by scaling directly with creatinine clearance relative to the $100$ mL/min reference. Round your final dose to three significant figures and express it in mg/day.\n\nIn your reasoning, you should also articulate the renal monitoring steps you would implement over the first month of therapy, but your final reported answer must be only the calculated daily maintenance dose in mg/day.", "solution": "The problem will be validated against the required criteria before a solution is attempted.\n\n### Step 1: Extract Givens\n- **Patient Demographics:** Age = $68$ years, Sex = female.\n- **Anthropometrics:** Height = $165$ cm, Total Body Weight (TBW) = $85$ kg.\n- **Clinical Condition:** Classical trigeminal neuralgia and refractory neuropathic orofacial pain.\n- **Comorbidities:** Stable chronic kidney disease.\n- **Pharmacogenomic Data:** HLA-B*15:02 positive, HLA-A*31:01 positive, $CYP2C9$ poor metabolizer genotype.\n- **Laboratory Data:** Estimated Glomerular Filtration Rate (eGFR) = $35$ mL/min per $1.73$ m$^2$, Serum Creatinine (SCr) = $1.8$ mg/dL.\n- **Pharmacokinetic Model:**\n    - Pregabalin exhibits linear pharmacokinetics.\n    - Clearance is almost entirely by renal excretion.\n    - Maintenance dose is directly proportional to creatinine clearance (CrCl).\n- **Reference Values:**\n    - Reference normal CrCl = $100$ mL/min.\n    - Usual effective maintenance dose for normal renal function = $600$ mg/day.\n- **Calculation Instructions:**\n    - Use the Cockcroft–Gault equation to estimate creatinine clearance.\n    - Use Adjusted Body Weight (AdjBW) if TBW exceeds $120\\%$ of Ideal Body Weight (IBW).\n    - Scale the maintenance dose directly with the calculated CrCl relative to the reference CrCl.\n    - Round the final dose to three significant figures.\n- **Additional Task:** Articulate renal monitoring steps for the first month of therapy.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated for validity.\n- **Scientifically Grounded:** The problem is grounded in established principles of clinical pharmacology and pharmacokinetics. The use of the Cockcroft-Gault equation for dose adjustment of renally cleared drugs is a standard clinical practice. The pharmacogenomic context (HLA-B*15:02 and HLA-A*31:01) justifying the avoidance of aromatic anticonvulsants (e.g., carbamazepine) and selecting pregabalin is clinically accurate and relevant. The provided patient data are plausible for an individual with chronic kidney disease.\n- **Well-Posed:** The problem is well-posed. It provides all necessary data (age, weight, height, sex, SCr) and a clear, unambiguous set of instructions for the calculation, including the specific formula (Cockcroft-Gault), the body weight convention, and the scaling relationship. A unique, stable, and meaningful solution can be determined.\n- **Objective:** The problem is stated objectively, presenting a clinical scenario and requesting a quantitative calculation based on formal models, free of subjective or opinion-based claims.\n\nThere are no identified flaws such as scientific unsoundness, incompleteness, contradiction, or ambiguity. The given eGFR of $35$ mL/min per $1.73$ m$^2$ is a standard laboratory report value (likely from an MDRD or CKD-EPI equation), while the instruction to use the Cockcroft-Gault equation for dosing is a common clinical workflow, as the latter is often preferred for drug dose adjustments. This does not represent a contradiction but a realistic clinical scenario.\n\n### Step 3: Verdict and Action\nThe problem is **valid**. A solution will be formulated.\n\n### Solution Derivation\nThe calculation proceeds in a stepwise manner as specified by the problem statement.\n\n**1. Calculation of Ideal Body Weight (IBW)**\nThe Devine formula is a standard method for calculating IBW. For a female, the formula is:\n$$ \\text{IBW (kg)} = 45.5 \\, \\text{kg} + 2.3 \\, \\text{kg for each inch of height over 5 feet} $$\nFirst, the patient's height is converted from centimeters to inches:\n$$ \\text{Height (in)} = \\frac{165 \\, \\text{cm}}{2.54 \\, \\text{cm/in}} \\approx 64.96 \\, \\text{in} $$\nThis height is equivalent to $5$ feet and $4.96$ inches.\nApplying the Devine formula:\n$$ \\text{IBW} = 45.5 + 2.3 \\times (64.96 - 60) = 45.5 + 2.3 \\times 4.96 = 45.5 + 11.408 = 56.908 \\, \\text{kg} $$\n\n**2. Determination of Dosing Weight**\nThe problem specifies using adjusted body weight (AdjBW) if the total body weight (TBW) is greater than $120\\%$ of the IBW.\n$$ 1.20 \\times \\text{IBW} = 1.20 \\times 56.908 \\, \\text{kg} = 68.29 \\, \\text{kg} $$\nThe patient's TBW is $85$ kg. Since $85 \\, \\text{kg} > 68.29 \\, \\text{kg}$, the condition is met, and AdjBW must be used for the Cockcroft-Gault calculation.\n\n**3. Calculation of Adjusted Body Weight (AdjBW)**\nThe standard formula for AdjBW is:\n$$ \\text{AdjBW} = \\text{IBW} + 0.4 \\times (\\text{TBW} - \\text{IBW}) $$\nSubstituting the values:\n$$ \\text{AdjBW} = 56.908 + 0.4 \\times (85 - 56.908) = 56.908 + 0.4 \\times (28.092) = 56.908 + 11.2368 = 68.1448 \\, \\text{kg} $$\n\n**4. Calculation of Creatinine Clearance (CrCl)**\nThe Cockcroft-Gault equation for a female patient is:\n$$ \\text{CrCl (mL/min)} = \\frac{(140 - \\text{Age}) \\times \\text{Weight (kg)}}{72 \\times \\text{SCr (mg/dL)}} \\times 0.85 $$\nUsing the patient's data and the calculated AdjBW as the weight term:\n- Age = $68$ years\n- Weight = AdjBW = $68.1448$ kg\n- SCr = $1.8$ mg/dL\n$$ \\text{CrCl} = \\frac{(140 - 68) \\times 68.1448}{72 \\times 1.8} \\times 0.85 $$\n$$ \\text{CrCl} = \\frac{72 \\times 68.1448}{129.6} \\times 0.85 $$\n$$ \\text{CrCl} = \\frac{4906.4256}{129.6} \\times 0.85 $$\n$$ \\text{CrCl} = 37.8582 \\times 0.85 = 32.1795 \\, \\text{mL/min} $$\nThe calculated CrCl of approximately $32$ mL/min is consistent with the provided eGFR of $35$ mL/min per $1.73$ m$^2$, granting confidence in the result.\n\n**5. Calculation of Adjusted Pregabalin Dose**\nThe problem states that the maintenance dose is directly proportional to CrCl, with a reference dose of $600$ mg/day corresponding to a reference CrCl of $100$ mL/min.\nThe dose adjustment is performed using a direct ratio:\n$$ \\text{Adjusted Dose} = \\text{Reference Dose} \\times \\frac{\\text{Patient's CrCl}}{\\text{Reference CrCl}} $$\n$$ \\text{Adjusted Dose} = 600 \\, \\text{mg/day} \\times \\frac{32.1795 \\, \\text{mL/min}}{100 \\, \\text{mL/min}} $$\n$$ \\text{Adjusted Dose} = 600 \\times 0.321795 = 193.077 \\, \\text{mg/day} $$\n\n**6. Final Answer Rounding**\nThe final dose must be rounded to three significant figures.\n$$ \\text{Adjusted Dose} \\approx 193 \\, \\text{mg/day} $$\nThis dose would typically be administered in a divided schedule, for example, $100$ mg in the morning and $100$ mg at night, or approximately $75$ mg twice daily initially, titrating up to a target of approximately $200$ mg/day total, as tolerated.\n\n### Renal Monitoring Protocol\nAs requested, a prudent renal monitoring strategy for the first month of therapy would be as follows:\n- **Baseline:** The baseline serum creatinine (SCr = $1.8$ mg/dL) and calculated CrCl (CrCl $\\approx 32$ mL/min) are established before initiating therapy.\n- **Week 1:** A repeat SCr measurement should be obtained within $5$ to $7$ days after starting pregabalin. This is to ensure that no acute deterioration in renal function has occurred and to confirm the patient's renal stability with the new medication.\n- **Month 1:** A follow-up SCr should be checked at the end of the first month, particularly if the dose has been titrated during this period. This confirms the steady-state renal function on a stable maintenance dose.\n- **Patient Counseling:** The patient must be counseled on the signs and symptoms of drug accumulation (e.g., excessive somnolence, dizziness, ataxia) and worsening renal function (e.g., edema, reduced urine output). This empowers the patient to report adverse effects promptly, which is crucial given the narrowed therapeutic window in renal impairment.\n\nThe final reportable answer is strictly the numerical value of the calculated daily dose.", "answer": "$$\n\\boxed{193}\n$$", "id": "4738357"}]}